153 related articles for article (PubMed ID: 34941590)
1. New Drug Treats Cervical Cancer.
Aschenbrenner DS
Am J Nurs; 2022 Jan; 122(1):21. PubMed ID: 34941590
[TBL] [Abstract][Full Text] [Related]
2. Tisotumab Vedotin: First Approval.
Markham A
Drugs; 2021 Dec; 81(18):2141-2147. PubMed ID: 34748188
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
[TBL] [Abstract][Full Text] [Related]
4. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Hong DS; Concin N; Vergote I; de Bono JS; Slomovitz BM; Drew Y; Arkenau HT; Machiels JP; Spicer JF; Jones R; Forster MD; Cornez N; Gennigens C; Johnson ML; Thistlethwaite FC; Rangwala RA; Ghatta S; Windfeld K; Harris JR; Lassen UN; Coleman RL
Clin Cancer Res; 2020 Mar; 26(6):1220-1228. PubMed ID: 31796521
[TBL] [Abstract][Full Text] [Related]
5. Tisotumab vedotin for the treatment of cervical carcinoma.
Song X; Li R; Wang H; Song P; Guo W; Chen ZS
Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
[TBL] [Abstract][Full Text] [Related]
6. Mitigation and management strategies for ocular events associated with tisotumab vedotin.
Kim SK; Ursell P; Coleman RL; Monk BJ; Vergote I
Gynecol Oncol; 2022 May; 165(2):385-392. PubMed ID: 35277279
[TBL] [Abstract][Full Text] [Related]
7. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
Heitz N; Greer SC; Halford Z
Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
[TBL] [Abstract][Full Text] [Related]
8. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
Luu K; Chu A; Chang B
J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
[TBL] [Abstract][Full Text] [Related]
9. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
10. Tisotumab Vedotin: The First FDA-Approved Antibody-Drug Conjugate for Cervical Cancer.
De SK
Anticancer Agents Med Chem; 2022 Aug; 22(16):2808-2810. PubMed ID: 35593349
[No Abstract] [Full Text] [Related]
11. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.
Yonemori K; Kuboki Y; Hasegawa K; Iwata T; Kato H; Takehara K; Hirashima Y; Kato H; Passey C; Buchbjerg JK; Harris JR; Andreassen CM; Nicacio L; Soumaoro I; Fujiwara K
Cancer Sci; 2022 Aug; 113(8):2788-2797. PubMed ID: 35633184
[TBL] [Abstract][Full Text] [Related]
12. Tisotumab vedotin in recurrent or metastatic cervical cancer.
Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Tannir NM; Forero-Torres A; Ramchandren R; Pal SK; Ansell SM; Infante JR; de Vos S; Hamlin PA; Kim SK; Whiting NC; Gartner EM; Zhao B; Thompson JA
Invest New Drugs; 2014 Dec; 32(6):1246-57. PubMed ID: 25142258
[TBL] [Abstract][Full Text] [Related]
14. Cadonilimab: First Approval.
Keam SJ
Drugs; 2022 Aug; 82(12):1333-1339. PubMed ID: 35986837
[TBL] [Abstract][Full Text] [Related]
15. [Targeted therapy in locally and metastatic recurrent cervical cancers].
Geiss R; De La Motte Rouge T; Dubot C; Leary A; Lhommé C; Pautier P; Scholl S; Rodrigues MJ
Bull Cancer; 2014; 101(7-8):748-55. PubMed ID: 25091657
[TBL] [Abstract][Full Text] [Related]
16. Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS; Monk BJ; Vergote I; Miller A; de Melo AC; Kim HS; Kim YM; Lisyanskaya A; Samouëlian V; Lorusso D; Damian F; Chang CL; Gotovkin EA; Takahashi S; Ramone D; Pikiel J; Maćkowiak-Matejczyk B; Guerra Alía EM; Colombo N; Makarova Y; Rischin D; Lheureux S; Hasegawa K; Fujiwara K; Li J; Jamil S; Jankovic V; Chen CI; Seebach F; Weinreich DM; Yancopoulos GD; Lowy I; Mathias M; Fury MG; Oaknin A;
N Engl J Med; 2022 Feb; 386(6):544-555. PubMed ID: 35139273
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer.
Tan SJ; Juan YH; Fu PT; Yu MH; Lai HC
Eur J Gynaecol Oncol; 2010; 31(3):350-3. PubMed ID: 21077488
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for recurrent and metastatic cervical cancer.
Tao X; Hu W; Ramirez PT; Kavanagh JJ
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239
[TBL] [Abstract][Full Text] [Related]
19. Cemiplimab shines for recurrent cervical cancer.
O'Rourke K
Cancer; 2022 Jun; 128(11):2050-2051. PubMed ID: 35532190
[No Abstract] [Full Text] [Related]
20. Cediranib aims for a comeback.
Schmidt C
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745013
[No Abstract] [Full Text] [Related]
[Next] [New Search]